Open Journal Systems

Effects of two myricetin on renal fibrosis in diabetic nephropathy rats

Zongliang Liu, Jiandong Zhang, Wan Peng, Zhen Wu, Hai Xiao

Article ID: 2101
Vol 4, Issue 1, 2023

DOI: https://doi.org/10.54517/urr.v2i2.2101
VIEWS - 65 (Abstract)

Abstract

Objective: To investigate the protective effect of two - myricetin (DMY) on diabetic nephropathy (DN) and its effect on renal fibrosis. Methods: the DN model was established by intraperitoneal injection of high-dose (55 mg · kg^-1) streptozotocin (STZ). The model was successfully established with blood glucose > 16.7 mmol · L^-1. The rats were randomly divided into normal group, model group and low, medium and high dose DMY group (125, 250 and 500 mg · kg^-1). DMY group was administered by gavage, and the model group was administered by normal saline for 12 weeks. The contents of 24h urinary protein (24h-Pro), blood urea nitrogen (BUN) and blood creatinine (SCR) were detected by biochemistry. He staining was used to observe the morphological changes of kidney in each group, PAS staining was used to observe the changes of basement membrane thickness of renal tissue in each group, and Masson staining was used to observe the degree of glomerulosclerosis and renal interstitial fibrosis in each group. TGF in renal tissue of rats in each group was detected by Western blot- β1. Expression level of Smad2 and Smad7. Results: compared with the normal group, the contents of 24h pro, bun and SCR in DN model group were significantly increased (P < 0.01). Compared with the model group, the contents of 24h pro, bun and SCR in each dose of DMY group decreased (P < 0.01). The pathological results showed that the renal tissue of the model group showed increased glomerular volume and glue more

Keywords

Diabetic nephropathy; Dihydromyricetin; Renal fibrosis; TGF- β1/Smads;

Full Text:

PDF

References

1. Xie Xiaodong Effect of Bailing Capsule on oxidative stress and renal function in diabetic kidney disease [J]. Journal of Gannan Medical College, 2018,38 (11): 1103-1104

2. Lan H Y.Transforming growth factor-beta / Smad signalling in diabetic nephropathy[J]. Clin Exp Pharmacol Physiol,2012,39(8):731-738.

3. Hills C E,Squires P E.The role of TGF-beta and epithelial-to mesenchymal transition in diabetic nephropathy[J]. Cytokine Growth Factor Rev,2011,22(3):131-139.

4. Chen Yali, Yin Yuefei, Li Yun, et al Research Progress on pharmacological action of Dihydromyricetin [J] Chinese Journal of new drugs, 2019,28 (2): 173-178

5. Liu L,Wan J,Lang H,et al.Dihydromyricetin delays the onset of hyperglycemia and ameliorates insulin resist- ance without excessive weight gain in Zucker diabetic fatty rats[J]. Mol Cell Endocrinol,2017,439:105-115.

6. LV Huijie, Xu Tuo, he Jianqin, et al Research progress of two hydrogen myricetin and diabetic nephropathy [J]. Journal of clinical and pathology, 2018,38 (10): 2233-2237

7. Zhou Haiyun, Wang Wenqing, Shi Chunyang, et al Research progress of Dihydromyricetin pharmacology and drug interaction [J] Chinese herbal medicine, 2018,49 (14): 3411-3418

8. Gan Lu, Deng Zhijing, Wang Xianzhe, et al Anti apoptotic effect and mechanism of Dihydromyricetin on focal cerebral ischemia / reperfusion injury in mice [J] Chinese contemporary medicine, 2018,25 (14): 4-8

9. Yun fengxiao, Wang Enhua, Qin Tian, et al Hypoglycemic effect of two myricetin on diabetic mice [J]. Pharmacology and clinic of traditional Chinese medicine, 2016,32 (3): 45-48

10. Wang Ying Protective effect of Dihydromyricetin on apoE (- / -) atherosclerotic mice and its mechanism [J] Chinese patent medicine, 2018,40 (3): 511-516

11. Xu Yanyan Protective effect of Dihydromyricetin on carbon tetrachloride induced liver fibrosis in rats and its mechanism [J] World clinical medicine, 2017,38 (8): 522-527

12. Guo Yanhua, Li Xiaolin, et al Effects of Dihydromyricetin on glomerular mesangial cell proliferation and fibronectin accumulation induced by high glucose [J] China pharmacy, 2017,28 (34): 4784-4787

13. Chen Hong, Gong Xinhua, Chen Lijun, et al Two hydrogen myricetin activates AMPK pathway to prevent diabetic nephropathy: [J]. Progress in modern biomedicine, 2017,17 (34): 6613-6619 + 6612

14. Tervaert T W,Mooyaart A L,Amann K,et al.Pathologic classification of diabetic nephropathy[J]. J Am Soc Nephrol,2010,21(4):556-563.

15. Wu Suzhen, Li Jialin, Wu Bing, et al Transforming growth factor- β The role of [J]. in glomerulosclerosis of diabetic nephropathy Journal of Gannan Medical College, 2017,37 (2): 312-316 + 337

16. Chang A S,Hathaway C K,Smithies O,et al.Transforming growth factor-beta1 and diabetic nephropathy[J]. Am J Physiol Renal Physiol,2016,310(8):689-696.

17. Zhao Y,Yin Z,Li H,et al.MiR-30c protects diabetic nephropathy by suppressing epithelial-to-mesenchymal transition in db / db mice[J]. Aging Cell,2017,16(2):387-400.

18. Loeffler I,Liebisch M,Allert S,et al.FSP1-specific SMAD2 knockout in renal tubular,endothelial,and in- terstitial cells reduces fibrosis and epithelial-to-mesen-chymal transition in murine STZ-induced diabetic ne- phropathy[J]. Cell Tissue Res,2018,372(1):115-133.

19. Hills C E,Squires P E.TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy [J]. Am J Nephrol ,2010,31(1):68-74.

20. Chen S,Iglesias-De La Cruz M C,Jim B,et al.Revers-ibility of established diabetic glomerulopathy by anti- TGF-beta antibodies in db / db mice[J]. Biochem Bio- phys Res Commun,2003,300(1):16-22.